|
|
|
|
|
|
|
|
| Hello awha hawhwa, |
|
To conclude our look back at Companisto portfolio companies, we turn our attention to DiaMonTech — a medtech company aiming to fundamentally transform the daily lives of millions of people worldwide.
The idea behind DiaMonTech arose from one of the biggest challenges in diabetes treatment. For many people with diabetes, daily blood sugar monitoring is part of their routine — usually involving regular finger pricks. While this method is well-established, it remains burdensome for many patients.
DiaMonTech is developing a technology that can measure blood sugar levels without needles, sensors, or consumables. Instead, DiaMonTech uses a physical method based on laser and infrared technology to measure glucose directly within the body.
In doing so, DiaMonTech is addressing a global market worth billions, where existing solutions face clear limitations. A widely available, non-invasive alternative has the potential to transform the market in the long term — with correspondingly significant economic potential.
As part of a follow-on funding round in early 2025, approximately 8 million euros were raised through Companisto. The round was primarily backed by Companists and supplemented by international venture capital firms and institutional investors — including Samsung Next, Unorthodox Ventures, the European Institute of Innovation & Technology (EIT), and a leading global medical technology company.
With this financing, the Companists demonstrated that private investors and business angels can play a key role not only in the early stages but also in complex follow-on rounds — on equal footing with VCs and institutional investors such as Samsung Next.
Today, DiaMonTech exemplifies the type of companies supported within the Companisto network: technologically sophisticated, with a clear vision and the potential to transform entire markets.
|
|
|
|
|
|
|
|
| Did you miss the funding round for DiaMonTech on Companisto? |
|
|
|
|
Starting April 29, 2026, you will have the opportunity to invest indirectly in DiaMonTech. From that date, an investment round for Companisto will be open for a limited time.
What makes investing in Companisto unique is that Companisto receives a “carry” from all startups funded through Companisto. This means that if a startup funded on Companisto generates profits or is sold (exit), Companisto receives a share of the profits from each startup.
This applies to all startups already funded in the past (over 100 active ones — including HERO, DiaMonTech, AMERIA, and many more) as well as to all startups funded in the future. Currently, 35 to 40 startups are funded through Companisto each year.
An investment in Companisto is therefore also an (indirect) investment in every startup ever funded through Companisto! |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
|
|
